Treatment of relapsed and refractory myeloma

References

• Canadian Cancer Society/National Cancer Institute of Canada: Canadian Cancer Statistics 2007. 2007, Toronto, Canada
   Google Scholar
• Attal M, Harousseau J L, Stoppa A M, Sotto J J, Fuzibet J G, Rossi J F, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–97
   PubMed Web of Science ®Google Scholar
• Child J A, Morgan G J, Davies F E, Owen R G, Bell S E, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883
   PubMed Web of Science ®Google Scholar
• Berenson J R, Crowley J J, Grogan T M, Zangmeister J, Briggs A D, Mills G M, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 2002; 99: 3163–3168
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau J L, Leyvraz S, Doyen C, Hulin C, Benboubker L, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006; 108: 3289–3294
   PubMed Web of Science ®Google Scholar
• Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J Clin Oncol 1998; 16: 3832–3842
   PubMed Web of Science ®Google Scholar
• Facon T, Mary J Y, Hulin C, Benboubker L, Attal M, Pegourie B, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007; 370: 1209–1218
   PubMed Web of Science ®Google Scholar
• Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen C, et al. Melphalan-prednisone-thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients ≥75 years with multiple myeloma compared with melphalan-prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01/01. Blood (ASH Annual Meeting Abstracts) 2007; 110: 75
   Web of Science ®Google Scholar
• San Miguel J F, Schlag R, Khuageva N, Shpilberg O, Dimopoulos M, Kropff M, et al. MMY-3002: a phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma. Blood (ASH Annual Meeting Abstracts) 2007; 110: 76
   Web of Science ®Google Scholar
• Belch A, Shelley W, Bergsagel D, Wilson K, Klimo P, White D, et al. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer 1988; 57: 94–99
   PubMed Web of Science ®Google Scholar
• Alexanian R, Gehan E, Haut A, Saiki J, Weick J. Unmaintained remissions in multiple myeloma. Blood 1978; 51: 1005–1011
   PubMed Web of Science ®Google Scholar
• Boccadoro M, Palumbo A, Bringhen S, Merletti F, Ciccone G, Richiardi L, et al. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica 2002; 87: 846–850
   PubMed Web of Science ®Google Scholar
• Kyle R A. Second malignancies associated with chemotherapeutic agents. Semin Oncol 1982; 9: 131–142
   PubMed Web of Science ®Google Scholar
• Kyle R A, Gailani S, Seligman B R, Blom J, McIntyre O R, Pajak T F, et al. Multiple myeloma resistant to melphalan: treatment with cyclophosphamide, prednisone, and BCNU. Cancer Treat Rep 1979; 63: 1265–1269
   PubMedGoogle Scholar
• Kyle R A, Seligman B R, Wallace H J, Jr, Silver R T, Glidewell O. Holland JF. Mutiple myeloma resistant to melphalan (NSC-8806) treated with cyclophosphamide (NSC-26271), prednisone (NSC-10023), and chloroquine (NSC-187208). Cancer Chemother Rep 1975; 59: 557–562
   PubMedGoogle Scholar
• de Weerdt O, van de Donk N W, Veth G, Bloem A C, Hagenbeek A, Lokhorst H M. Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma. Neth J Med 2001; 59: 50–56
   PubMed Web of Science ®Google Scholar
• Lenhard R E, Daniels M J, Oken M M, Glick J H, Ettinger D S, Kalish L, et al. An aggressive high dose cyclophosphamide and prednisone regimen for advanced multiple myeloma. Leuk Lymphoma 1994; 13: 485–489
   PubMed Web of Science ®Google Scholar
• Wilson K, Shelley W, Belch A, Brandes L, Bergsagel D, Klimo P, et al. Weekly cyclophosphamide and alternate-day prednisone: an effective secondary therapy in multiple myeloma. Cancer Treat Rep 1987; 71: 981–982
   PubMedGoogle Scholar
• Brandes L J, Israels L G. Weekly low-dose cyclophosphamide and alternate-day prednisone: an effective low toxicity regimen for advanced myeloma. Eur J Haematol 1987; 39: 362–368
   PubMed Web of Science ®Google Scholar
• Trieu Y, Trudel S, Pond G R, Mikhael J, Jaksic W, Reece D E, et al. Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation. Mayo Clin Proc 2005; 80: 1578–1582
   PubMed Web of Science ®Google Scholar
• Dalton W S, Crowley J J, Salmon S S, Grogan T M, Laufman L R, Weiss G R, et al. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. Cancer 1995; 75: 815–820
   PubMed Web of Science ®Google Scholar
• Mineur P, Menard J F, Le Loet X, Bernard J F, Grosbois B, Pollet J P, et al. VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide-prednisone therapy (protocol MY 85). Br J Haematol 1998; 103: 512–517
   PubMed Web of Science ®Google Scholar
• Friedenberg W R, Rue M, Blood E A, Dalton W S, Shustik C, Larson R A, et al. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer 2006; 106: 830–838
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Suciu S, Weijermans P, Beksac M, Neuwirtova R, Solbu G, et al. Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). Br J Haematol 2001; 115: 895–902
   PubMed Web of Science ®Google Scholar
• Phillips J K, Sherlaw-Johnson C, Pearce R, Davies J M, Reilly J T, Newland A C, et al. A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma. Leuk Lymphoma 1995; 17: 465–472
   PubMed Web of Science ®Google Scholar
• Gertz M A, Kalish L A, Kyle R A, Hahn R G, Tormey D C, Oken M M. Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group study. Am J Clin Oncol 1995; 18: 475–480
   PubMed Web of Science ®Google Scholar
• Egerer G, Hegenbart U, Salwender H, Haas R, Hahn U, Schmier J W, et al. Outpatient treatment of multiple myeloma with a combination of vincristine, adriamycin and dexamethasone. Support Care Cancer 2001; 9: 380–385
   PubMed Web of Science ®Google Scholar
• Anderson H, Scarffe J H, Ranson M, Young R, Wieringa G S, Morgenstern G R, et al. VAD chemotherapy as remission induction for multiple myeloma. Br J Cancer 1995; 71: 326–330
   PubMed Web of Science ®Google Scholar
• Alexanian R, Barlogie B, Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 1986; 105: 8–11
   PubMed Web of Science ®Google Scholar
• Lokhorst H M, Meuwissen O J, Bast E J, Dekker A W. VAD chemotherapy for refractory multiple myeloma. Br J Haematol 1989; 71: 25–30
   PubMed Web of Science ®Google Scholar
• Scheithauer W, Cortelezzi A, Kutzmits R, Baldini L, Ludwig H. VAD protocol for treatment of advanced refractory multiple myeloma. Blut 1987; 55: 145–152
   PubMedGoogle Scholar
• Palva I P, Ahrenberg P, Ala Harja K, Almqvist A, Elonen E, Hallman H, et al. Intensive chemotherapy with combinations containing anthracyclines for refractory and relapsing multiple myeloma. Finnish Leukaemia Group. Eur J Haematol 1990; 44: 121–124
   PubMedGoogle Scholar
• Browman G P, Belch A, Skillings J, Wilson K, Bergsagel D, Johnston D, et al. Modified adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study. The National Cancer Institute of Canada Clinical Trials Group. Br J Haematol 1992; 82: 555–559
   PubMed Web of Science ®Google Scholar
• Segeren C M, Sonneveld P, van der Holt B, Baars J W, Biesma D H, Cornellissen J J, et al. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br J Haematol 1999; 105: 127–130
   PubMed Web of Science ®Google Scholar
• Jackson D V, Case L D, Pope E K, White D R, Spurr C L, Richards F, II, et al. Single agent vincristine by infusion in refractory multiple myeloma. J Clin Oncol 1985; 3: 1508–1512
   PubMed Web of Science ®Google Scholar
• Alberts D S, Salmon S E. Adriamycin (NSC-123127) in the treatment of alkylator-resistant multiple myeloma: a pilot study. Cancer Chemother Rep 1975; 59: 345–350
   PubMedGoogle Scholar
• Bennett J M, Silber R, Ezdinli E, Levitt M, Oken M, Bakemeier R F, et al. Phase II study of adriamycin and bleomycin in patients with multiple myeloma. Cancer Treat Rep 1978; 62: 1367–1369
   PubMedGoogle Scholar
• Friedenberg W R, Kyle R A, Knospe W H, Bennett J M, Tsiatis A A, Oken M M. High-dose dexamethasone for refractory or relapsing multiple myeloma. Am J Hematol 1991; 36: 171–175
   PubMed Web of Science ®Google Scholar
• Richardson P G, Sonneveld P, Schuster M W, Irwin D, Stadtmauer E A, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–2498
   PubMed Web of Science ®Google Scholar
• Richardson P G, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007; 110: 3557–3560
   PubMed Web of Science ®Google Scholar
• Weber D M, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer E A, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133–2142
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M, Prince H M, Harousseau J L, Dmoszynska A, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123–2132
   PubMed Web of Science ®Google Scholar
• Gertz M A, Garton J P, Greipp P R, Witzig T E, Kyle R A. A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma. Leukemia 1995; 9: 2115–2118
   PubMed Web of Science ®Google Scholar
• Forgeson G V, Selby P, Lakhani S, Zulian G, Viner C, Maitland J, et al. Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients. Br J Cancer 1988; 58: 469–473
   PubMed Web of Science ®Google Scholar
• Alexanian R, Yap B S, Bodey G P. Prednisone pulse therapy for refractory myeloma. Blood 1983; 62: 572–577
   PubMed Web of Science ®Google Scholar
• Lee C K, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003; 21: 2732–2739
   PubMed Web of Science ®Google Scholar
• Munshi N, Desikan K, Jagannath S, Siegel D, Bracy D, Tricot G, et al. Dexamethasone, cyclophosphamide, etoposide and cis-platinum (DCEP), an effective regimen for relapse after high-dose chemotherapy and autologous transplantation (AT). Blood (ASH Annual Meeting Abstracts) 1996; 88: 2331
   Web of Science ®Google Scholar
• Gerrie A S, Xu W, Fung S, Stewart A K, Reece D, Trudel S, et al. Retrospective review of DPACE therapy for aggressive, refractory multiple myeloma (MM). J Clin Oncol (ASCO Annual Meeting Abstracts) 2007; 25: 18500
   Google Scholar
• McBride W. Thalidomide and congenital abnormalities. Lancet 1961; 2: 1358
   Web of Science ®Google Scholar
• Parman T, Wiley M J, Wells P G. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med 1999; 5: 582–585
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565–1571
   PubMed Web of Science ®Google Scholar
• Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492–494
   PubMed Web of Science ®Google Scholar
• Glasmacher A, Hahn C, Hoffmann F, Naumann R, Goldschmidt H, von Lilienfeld-Toal M, et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2006; 132: 584–593
   PubMed Web of Science ®Google Scholar
• Prince H M, Schenkel B, Mileshkin L. An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma. Leuk Lymphoma 2007; 48: 46–55
   PubMed Web of Science ®Google Scholar
• Yakoub-Agha I, Doyen C, Hulin C, Marit G, Voillat L, Grosbois B, et al. A multicenter prospective randomized study testing non-inferiority of thalidomide 100 mg/day as compared with 400 mg/day in patients with refractory/relapsed multiple myeloma: results of the final analysis of the IFM 01-02 study. J Clin Oncol (ASCO Annual Meeting Abstracts) 2006; 24: 7520
   Google Scholar
• Neben K, Moehler T, Benner A, Kraemer A, Egerer G, Ho A D, et al. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 2002; 8: 3377–3382
   PubMed Web of Science ®Google Scholar
• Mileshkin L, Biagi J J, Mitchell P, Underhill C, Grigg A, Bell R, et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 2003; 102: 69–77
   PubMed Web of Science ®Google Scholar
• Schey S A, Cavenagh J, Johnson R, Child J A, Oakervee H, Jones R W. An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment. Leuk Res 2003; 27: 909–914
   PubMed Web of Science ®Google Scholar
• Waage A, Gimsing P, Juliusson G, Turesson I, Gulbrandsen N, Eriksson T, et al. Early response predicts thalidomide efficiency in patients with advanced multiple myeloma. Br J Haematol 2004; 125: 149–155
   PubMed Web of Science ®Google Scholar
• Tosi P, Zamagni E, Cellini C, Ronconi S, Patriarca F, Ballerini F, et al. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica 2002; 87: 408–414
   PubMed Web of Science ®Google Scholar
• Hus M, Dmoszynska A, Soroka-Wojtaszko M, Jawniak D, Legiec W, Ciepnuch H, et al. Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica 2001; 86: 404–408
   PubMed Web of Science ®Google Scholar
• Kumar S, Gertz M A, Dispenzieri A, Lacy M Q, Geyer S M, Iturria N L, et al. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc 2003; 78: 34–39
   PubMed Web of Science ®Google Scholar
• Richardson P, Schlossman R, Jagannath S, Alsina M, Desikan R, Blood E, et al. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc 2004; 79: 875–882
   PubMed Web of Science ®Google Scholar
• Fermand J-P, Jaccard A, Macro M, Uzunhan Y, Allard C, Castaigne S, et al. A randomized comparison of dexamethasone + thalidomide (Dex/Thal) vs. Dex + placebo (Dex/P) in patients (pts) with relapsing multiple myeloma (MM). Blood 2006; 108: 3563
   Google Scholar
• Palumbo A, Giaccone L, Bertola A, Pregno P, Bringhen S, Rus C, et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 2001; 86: 399–403
   PubMed Web of Science ®Google Scholar
• Murakami H, Handa H, Abe M, Iida S, Ishii A, Ishikawa T, et al. Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma. Eur J Haematol 2007; 79: 234–239
   PubMed Web of Science ®Google Scholar
• Dimopoulos M A, Zervas K, Kouvatseas G, Galani E, Grigoraki V, Kiamouris C, et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001; 12: 991–995
   PubMed Web of Science ®Google Scholar
• Terpos E, Mihou D, Szydlo R, Tsimirika K, Karkantaris C, Politou M, et al. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia 2005; 19: 1969–1976
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bertola A, Falco P, Rosato R, Cavallo F, Giaccone L, et al. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J 2004; 5: 318–324
   PubMedGoogle Scholar
• Palumbo A, Falco P, Ambrosini M T, Petrucci M T, Musto P, Caravita T, et al. Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant. Eur J Haematol 2005; 75: 391–395
   PubMed Web of Science ®Google Scholar
• Garcia-Sanz R, Gonzalez-Porras J R, Hernandez J M, Polo-Zarzuela M, Sureda A, Barrenetxea C, et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia 2004; 18: 856–863
   PubMed Web of Science ®Google Scholar
• Kropff M H, Lang N, Bisping G, Domine N, Innig G, Hentrich M, et al. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol 2003; 122: 607–616
   PubMed Web of Science ®Google Scholar
• Moehler T M, Neben K, Benner A, Egerer G, Krasniqi F, Ho A D, et al. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood 2001; 98: 3846–3848
   PubMed Web of Science ®Google Scholar
• Dimopoulos M A, Hamilos G, Zomas A, Gika D, Efstathiou E, Grigoraki V, et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J 2004; 5: 112–117
   PubMedGoogle Scholar
• Kyriakou C, Thomson K, D'Sa S, Flory A, Hanslip J, Goldstone A H, et al. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br J Haematol 2005; 129: 763–770
   PubMed Web of Science ®Google Scholar
• Offidani M, Corvatta L, Marconi M, Visani G, Alesiani F, Brunori M, et al. Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study. Haematologica 2006; 91: 133–136
   PubMed Web of Science ®Google Scholar
• Hussein M A, Baz R, Srkalovic G, Agrawal N, Suppiah R, Hsi E, et al. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clin Proc 2006; 81: 889–895
   PubMed Web of Science ®Google Scholar
• Hovenga S, Daenen S M, de Wolf J T, van Imhoff G W, Kluin-Nelemans H C, Sluiter W J, et al. Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study. Ann Hematol 2005; 84: 311–316
   PubMed Web of Science ®Google Scholar
• Suvannasankha A, Fausel C, Juliar B E, Yiannoutsos C T, Fisher W B, Ansari R H, et al. Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21. Oncologist 2007; 12: 99–106
   PubMed Web of Science ®Google Scholar
• Palumbo A, Avonto I, Bruno B, Ambrosini M T, Bringhen S, Cavallo F, et al. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma. Eur J Haematol 2006; 76: 273–277
   PubMed Web of Science ®Google Scholar
• Offidani M, Corvatta L, Marconi M, Olivieri A, Catarini M, Mele A, et al. Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma. Hematol J 2004; 5: 312–317
   PubMedGoogle Scholar
• Offidani M, Bringhen S, Corvatta L, Falco P, Marconi M, Avonto I, et al. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma. Eur J Haematol 2007; 78: 297–302
   PubMed Web of Science ®Google Scholar
• Wulff C H, Hoyer H, Asboe-Hansen G, Brodthagen H. Development of polyneuropathy during thalidomide therapy. Br J Dermatol 1985; 112: 475–480
   PubMed Web of Science ®Google Scholar
• Mileshkin L, Stark R, Day B, Seymour J F, Zeldis J B, Prince H M. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006; 24: 4507–4514
   PubMed Web of Science ®Google Scholar
• Tosi P, Zamagni E, Cellini C, Plasmati R, Cangini D, Tacchetti P, et al. Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol 2005; 74: 212–216
   PubMed Web of Science ®Google Scholar
• Cibeira M T, Rosinol L, Ramiro L, Esteve J, Torrebadell M, Blade J. Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration. Eur J Haematol 2006; 77: 486–492
   PubMed Web of Science ®Google Scholar
• Ikhlaque N, Seshadri V, Kathula S, Baumann M A. Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis. Am J Hematol 2006; 81: 420–422
   PubMed Web of Science ®Google Scholar
• Minnema M C, Breitkreutz I, Auwerda J J, van der Holt B, Cremer F W, van Marion A M, et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 2004; 18: 2044–2046
   PubMed Web of Science ®Google Scholar
• Baz R, Li L, Kottke-Marchant K, Srkalovic G, McGowan B, Yiannaki E, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 2005; 80: 1568–1574
   PubMed Web of Science ®Google Scholar
• Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson P G, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127: 165–172
   PubMed Web of Science ®Google Scholar
• Richardson P G, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609–2617
   PubMed Web of Science ®Google Scholar
• Richardson P G, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D H, et al. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer 2006; 106: 1316–1319
   PubMed Web of Science ®Google Scholar
• Orlowski R Z, Nagler A, Sonneveld P, Blade J, Hajek R, Spencer A, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007; 25: 3892–3901
   PubMed Web of Science ®Google Scholar
• Harousseau J L, Nagler A, Sonneveld P, Blade J, Hajek R, Spencer A, et al. Effect of the combination of pegylated liposomal doxorubicin and bortezomib on time to progression (TTP) and overall survival of patients with relapsed/refractory multiple myeloma compared with bortezomib alone. J Clin Oncol (ASCO Annual Meeting Abstracts) 2007; 25: 8002
   Google Scholar
• Kropff M, Bisping G, Schuck E, Liebisch P, Lang N, Hentrich M, et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol 2007; 138: 330–337
   PubMed Web of Science ®Google Scholar
• Berenson J R, Yang H H, Sadler K, Jarutirasarn S G, Vescio R A, Mapes R, et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006; 24: 937–944
   PubMed Web of Science ®Google Scholar
• Palumbo A, Ambrosini M T, Benevolo G, Pregno P, Pescosta N, Callea V, et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 2007; 109: 2767–2772
   PubMed Web of Science ®Google Scholar
• Suvannasankha A, Smith G G, Juliar B E, Abonour R. Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma. Clin Lymphoma Myeloma 2006; 7: 131–134
   PubMedGoogle Scholar
• Berenson J R, Matous J, Swift R A, Mapes R, Morrison B, Yeh H S. A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res 2007; 13: 1762–1768
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Richardson P G, Schuster M W, Irwin D, Stadtmauer E A, Facon T, et al. Bortezomib is more effective than high-dose dexamethasone at first relapse and provides better outcomes when used early rather than as later salvage therapy in relapsed multiple myeloma. Haematologica (10th Congress of the European Hematology Association) 2005; 90: 400
   PubMed Web of Science ®Google Scholar
• Richardson P G, Briemberg H, Jagannath S, Wen P Y, Barlogie B, Berenson J, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006; 24: 3113–3120
   PubMed Web of Science ®Google Scholar
• Mulkerin D, Remick S, Ramanathan R, Hamilton A, Takimoto C, Davies A, et al. A dose-escalating and pharmacologic study of bortezomib in adult cancer patients with impaired renal function. J Clin Oncol (ASCO Annual Meeting Abstracts) 2006; 24: 2032
   Google Scholar
• Jagannath S, Barlogie B, Berenson J R, Singhal S, Alexanian R, Srkalovic G, et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer 2005; 103: 1195–1200
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A A, Kaufman J L, Mehta J, Richardson P G, Miller K C, Lonial S, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 2007; 109: 2604–2606
   PubMed Web of Science ®Google Scholar
• Berenson J R, Jagannath S, Barlogie B, Siegel D T, Alexanian R, Richardson P G, et al. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer 2005; 104: 2141–2148
   PubMed Web of Science ®Google Scholar
• Druck M, Walters I B, Carloss H, Sood R, Leblanc A L, Noga S J. A phase IV, open-label trial using bortezomib for retreatment of patients (pts) with multiple myeloma (MM) following an initial response to bortezomib. J Clin Oncol (ASCO Annual Meeting Abstracts) 2006; 24: 17539
   Google Scholar
• Richardson P G, Sonneveld P, Schuster M W, Irwin D, Stadtmauer E A, Facon T, et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol 2007; 137: 429–435
   PubMed Web of Science ®Google Scholar
• San Miguel J F, Hajek R, Nagler A, Sonneveld P, Spencer A, Blade J, et al. Doxil + velcade in previously treated ≥65Y myeloma pts. Haematologica (XIth International Myeloma Workshop Meeting Abstracts) 2007; 92: 620
   Google Scholar
• Spencer A, Hajek R, Nagler A, Sonneveld P, Blade J, Robak T, et al. Doxil + velcade in previously treated high risk myeloma. Haematologica (XIth International Myeloma Workshop Meeting Abstracts) 2007; 92: 629
   Google Scholar
• Jagannath S, Richardson P G, Sonneveld P, Schuster M W, Irwin D, Stadtmauer E A, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007; 21: 151–157
   PubMed Web of Science ®Google Scholar
• Chang H, Trieu Y, Qi X, Xu W, Stewart K A, Reece D. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leuk Res 2007; 31: 779–782
   PubMed Web of Science ®Google Scholar
• Sagaster V, Ludwig H, Kaufmann H, Odelga V, Zojer N, Ackermann J, et al. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia 2007; 21: 164–168
   PubMed Web of Science ®Google Scholar
• Richardson P G, Blood E, Mitsiades C S, Jagannath S, Zeldenrust S R, Alsina M, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006; 108: 3458–3464
   PubMed Web of Science ®Google Scholar
• Baz R, Walker E, Karam M A, Choueiri T K, Jawde R A, Bruening K, et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol 2006; 17: 1766–1771
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A A, Weber D, Dimopoulos M, Chen C, Niesvizky R, Wang M, et al. Lenalidomide (L) in combination with dexamethasone (D) improves survival and time to progression in elderly patients (pts) with relapsed or refractory (rel/ref) multiple myeloma (MM). Blood 2006; 108: 3551
   Google Scholar
• Niesvizky R, Martinez-Banos D, Jalbrzikowski J, Christos P, Furst J, De Sancho M, et al. Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leuk Lymphoma 2007; 48: 2330–2337
   PubMed Web of Science ®Google Scholar
• Bahlis N J, Song K, Trieu Y, Roland B, Masih-Khan E, Chang H, et al. Lenalidomide overcomes poor prognosis conferred by del13q and t(4;14) but Not del17p13 in multiple myeloma: results of the Canadian MM016 trial. Blood 2007; 110: 3597
   Google Scholar
• Sirohi B, Powles R, Singhal S, Treleaven J, Kulkami S, Sankpal S, et al. Second high-dose melphalan autografts for myeloma patients relapsing after one autograft: results equivalent to tandem transplantation. Bone Marrow Transplant (EBMT Annual Meeting Abstracts) (abstr 121) 2002; 29(Suppl 2)121
   PubMed Web of Science ®Google Scholar
• Mikhael J R, Samiee S, Stewart A K, Chen C, Trudel S, Franke N, et al. Outcome after second autologous stem cell transplantation as salvage therapy in patients with relapsed multiple myeloma. Blood 2004; 104: 943
   Google Scholar
• Vogl D T, Stadtmauer E, Richardson P G, Sonneveld P, Schuster M W, Irwin D, et al. Impact of prior autologous stem cell transplant (ASCT) in patients receiving bortezomib or dexamethasone for relapsed/refractory multiple myeloma in the APEX trial. J Clin Oncol (ASCO Annual Meeting Abstracts) 2006; 24: 7546
   Google Scholar
• Chanan-Khan A A, Yu Z, Weber D, Chen C, Niesvizky R, Spencer A, et al. Lenalidomide (L) in combination with dexamethasone (D) significantly improves time to progression (TTP) in non-stem cell transplant patients (pts) with relapsed or refractory (rel/ref) multiple myeloma (MM): analysis from MM-009 and MM-010 randomized phase III clinical trials. Blood 2006; 108: 3554
   Google Scholar
• Nagler A, Hajek R, Sonneveld P, Spencer A, Blade J, Robak T, et al. Doxil + velcade in previously treated myeloma w/ prior SCT. Haematologica (XIth International Myeloma Workshop Meeting Abstracts) 2007; 92: 625
   Google Scholar
• Rajkumar S V, Blood E, Vesole D, Fonseca R, Greipp P R. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431–436
   PubMed Web of Science ®Google Scholar
• Rajkumar S V, Hussein M, Catalano L, Jedrzejcak W, Sirkovich S, Olesnyckyj M, et al. A multicenter, randomized, double-blind, placebo-controlled trial of thalidomide plus dexamethasone versus dexamethasone alone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol (ASCO Annual Meeting Abstracts) 2006; 24: 7517
   Google Scholar
• Zervas K, Mihou D, Katodritou E, Pouli A, Mitsouli C H, Anagnostopoulos A, et al. VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study Group. Ann Oncol 2007; 18: 1369–1375
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Caravita T, Merla E, Caparella V, Callea V, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367: 825–831
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Hajek R, Nagler A, Spencer A, Blade J, Robak T, et al. Impact of prior thalidomide (T) therapy on the efficacy of pegylated liposomal doxorubicin (PLD) and bortezomib (B) in relapsed/refractory multiple myeloma (RRMM). J Clin Oncol (ASCO Annual Meeting Abstracts) 2007; 25: 8023
   Google Scholar
• Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021–1030
   PubMed Web of Science ®Google Scholar
• Wang M, Knight R, Dimopoulos M, Siegel D, Rajkumar S V, Facon T, et al. Lenalidomide in combination with dexamethasone was more effective than dexamethasone in patients who have received prior thalidomide for relapsed or refractory multiple myeloma. Blood 2006; 108: 3553
   Google Scholar
• Kumar S K, Therneau T M, Gertz M A, Lacy M Q, Dispenzieri A, Rajkumar S V, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 2004; 79: 867–874
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Richardson P G, Sonneveld P, Schuster M W, Coleman M, Irwin D, et al. Relationship between quality of response to bortezomib (btz) and clinical benefit in multiple myeloma (MM) in the APEX and SUMMIT studies. Blood 2006; 108: 3529
   Google Scholar
• Harousseau J L, Weber D, Dimopoulos M, Olesnyckyj M, Yu Z, Zeldis J, et al. Relapsed/refractory multiple myeloma patients treated with lenalidomide/dexamethasone who achieve a complete or near complete response have longer overall survival and time to progression compared with patients achieving a partial response. Blood 2007; 110: 3598
   Google Scholar